| Patient | Frederick Cook |
|---|---|
| Date of birth | 1865-06-10 |
| Identifiers | MRN HR-EX006-SYN-TD; SSN (made up) 000-06-4471 |
| Document date | 1930-09-29 |
| Author | Harriet Okafor-Brandt, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Twelve-week review of blood pressure and lipids three weeks after a gout flare on hydrochlorothiazide. [S]
Mr. Cook returns three weeks after the same-day visit for gout of his right big toe. The pain settled within four days of colchicine, he took the last tablet five days after starting, and he had no diarrhea or muscle aches. He has had no further attacks. He continues hydrochlorothiazide, amlodipine, atorvastatin and aspirin without missed doses. His home readings average 132/80. He has had no stroke symptoms. His Social Security retirement benefits and Medicare have been approved, and he has signed a six-month lease on his room. He is writing most mornings and says he feels steadier. [S]
| Element | Detail |
|---|---|
| Gout | Settled within four days on colchicine; no further attacks |
| Home blood pressure | Average 132/80 |
| Medicine effects | No diarrhea, muscle aches or bleeding |
| Social | Benefits and Medicare approved; six-month lease |
| System | Result | Finding |
|---|---|---|
| Musculoskeletal | Negative | Right big toe back to normal; no other joint pain; no muscle aches |
| Cardiovascular | Negative | No chest pain or ankle swelling |
| Neurological | Negative | No weakness, numbness, speech trouble, or loss of vision |
| Psychiatric | Negative | Mood steadier; no thoughts of self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydrochlorothiazide 25 mg tablet, one tablet by mouth each morning | once daily in the morning | Oral route | 1930-07-21 to 1930-09-29 | completed | S |
| Amlodipine 5 mg tablet, one tablet by mouth daily | once daily | Oral route | 1930-07-21 | active | S |
| Atorvastatin 40 mg tablet, one tablet by mouth daily | once daily | Oral route | 1930-07-21 | active | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth daily | once daily | Oral route | 1930-07-21 | active | S |
| Losartan 50 mg tablet, one tablet by mouth daily | once daily | Oral route | 1930-09-29 | active | S |
| Colchicine 0.6 mg tablet: two tablets at once, one more an hour later, then one tablet twice a day until the flare settles, for up to a week | 1.2 mg, then 0.6 mg an hour later, then 0.6 mg twice daily for up to a week | Oral route | 1930-09-08 to 1930-09-13 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1930-09-29 | Body height | 175 | cm | S |
| 1930-09-29 | Body weight | 75 | kg | S |
| 1930-09-29 | Body mass index (BMI) [Ratio] | 24.5 | kg/m2 | S |
| 1930-09-29 | Systolic blood pressure | 134 | mm[Hg] | S |
| 1930-09-29 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1930-09-29 | Heart rate | 68 | /min | S |
| 1930-09-29 | Respiratory rate | 14 | /min | S |
| 1930-09-29 | Body temperature | 36.5 | Cel | S |
| 1930-09-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1930-09-29 | Urate [Mass/volume] in Serum or Plasma | 8.4 | mg/dL | 3.5-7.2 mg/dL | High | S |
| 1930-09-29 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 136-145 mmol/L | Normal | S |
| 1930-09-29 | Potassium [Moles/volume] in Serum or Plasma | 3.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1930-09-29 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1930-09-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1925)/1.73 sq M | 80 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 1930-09-29 | Cholesterol [Mass/volume] in Serum or Plasma | 142 | mg/dL | <=199 mg/dL | Normal | S |
| 1930-09-29 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 48 | mg/dL | >=40 mg/dL | Normal | S |
| 1930-09-29 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 68 | mg/dL | Below 100 | Normal | S |
| 1930-09-29 | Triglyceride [Mass/volume] in Serum or Plasma | 130 | mg/dL | <=149 mg/dL | Normal | S |
| 1930-09-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-52 U/L | Normal | S |
Vital signs recorded on 1930-09-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 134/80, pulse 68, weight 75.0 kg |
| Right foot | First metatarsophalangeal joint normal, no swelling or tenderness; no tophi |
| Neck | Soft right carotid bruit, unchanged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Elevated blood pressure at the first visit, 166/94 mmHg (average of two seated readings), without a previous diagnosis of hypertension; no symptoms; out-of-office confirmation with a week of home readings requested | resolved | confirmed | R03.0 | S — Synthetic presenting finding at re-entry; superseded by the diagnosis at the second visit. |
| Essential hypertension, stage 2, confirmed by home readings averaging 154/90 mmHg; no left ventricular hypertrophy on ECG; urine albumin normal | active | confirmed | I10 | S — Synthetic modern diagnosis made at the second visit. |
| Right carotid bruit heard at the first visit in a man with no symptoms of stroke or transient ischemic attack; carotid duplex ultrasound and vascular neurology consultation requested | resolved | confirmed | R09.89 | S — Synthetic examination finding; superseded by the duplex result at the second visit. |
| Asymptomatic atherosclerotic stenosis of the right internal carotid artery, 50 to 69 percent by duplex ultrasound, with less than 50 percent plaque on the left; no stroke or transient ischemic attack; managed with best medical therapy (blood pressure control, a statin and low-dose aspirin) and yearly duplex surveillance | active | confirmed | I65.21 | S — Synthetic modern diagnosis made at the vascular neurology consultation; not a claim about his real arteries. |
| Recent release from about six years of incarceration: re-entering community life on parole at 65, establishing primary care with no medical records yet received, a rented room, no earned income, and a public reputation he feels as a burden | active | confirmed | Z65.2 | S — Synthetic modern social problem anchored to his documented imprisonment and parole. |
| Acute gout of the right first metatarsophalangeal joint, a first flare seven weeks after starting hydrochlorothiazide, diagnosed clinically (sudden overnight onset, redness, swelling and exquisite tenderness of the big toe, no fever); treated with low-dose colchicine; resolved | resolved | confirmed | M10.271 | S — Synthetic adverse drug effect; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure, seated, average of two readings | Every visit | Completed today | 134/80 mmHg |
| Self-management | Home blood pressure monitoring | At diagnosis and after each treatment change | Completed today | Average 132/80; repeat after the switch to losartan |
| Laboratory | Sodium, potassium, creatinine and eGFR | Baseline; early after starting a diuretic or an ARB; then every 6 months | Completed today | Sodium 137, potassium 3.7 mmol/L, creatinine 1.04 mg/dL, eGFR 80; baseline before losartan; repeat ordered for one to two weeks after starting |
| Laboratory | Lipid panel | Baseline; 4 to 12 weeks after starting a statin; then every 3 to 12 months | Completed today | Total cholesterol 142, HDL 48, LDL 68, triglycerides 130 mg/dL, ten weeks after starting atorvastatin; LDL down 54 percent |
| Laboratory | ALT on a statin | Baseline, then with the first lipid check or with symptoms | Completed today | 26 U/L |
| Laboratory | Serum urate after a gout flare | Two to four weeks after the flare settles, and on any change in therapy | Completed today | 8.4 mg/dL on hydrochlorothiazide |
| Medication safety | Review of drugs that raise urate | After a gout flare | Completed today | Hydrochlorothiazide stopped; losartan started; low-dose aspirin continued because its benefit outweighs its small effect on urate |
| Medication safety | Urate-lowering therapy | After each flare | Not indicated | Single flare; no kidney disease, tophi, stones, or urate above 9 mg/dL |
| Medication safety | Antiplatelet adherence and bleeding | Every visit | Completed today | No bleeding |
| Medication safety | Statin adherence and muscle symptoms | Every visit | Completed today | No muscle symptoms, including during colchicine |
| Imaging | Carotid duplex ultrasound for known 50 percent or greater stenosis on medical therapy | At diagnosis, then yearly | Up to date | Next duplex due in about ten months |
| Self-management | Stroke warning signs (BE FAST) and calling 911 | Every visit | Completed today | No symptoms |
| Survey | Depression screen (PHQ-9) | Annually | Up to date | PHQ-9 7 at intake; mood steadier by interview; repeat planned at the next visit |
| Self-management | Re-entry social needs: housing, income, benefits, records | Every visit until settled | Completed today | Social Security and Medicare approved; six-month lease |
Goal progress:
Immunizations given today: Hepatitis B vaccine, CpG-adjuvanted (two-dose series), dose 2 of 2 [S]
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (Jones DW, et al. Hypertension 2025;82:e212-e316) (2025); CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and stroke/TIA monographs (2026); 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association (Bushnell C, et al. Stroke 2024;55:e344-e424) (2024); 2018 AHA/ACC Guideline on the Management of Blood Cholesterol (Grundy SM, et al. Circulation 2019;139:e1082-e1143) (2018); 2020 American College of Rheumatology Guideline for the Management of Gout (FitzGerald JD, et al. Arthritis Care Res 2020;72(6):744-760) (2020)
Follow-up: Potassium and creatinine in one to two weeks. Review in four weeks. Next scheduled visit 1930-10-27: sixteen-week review: blood pressure, potassium and kidney function on losartan, mood, social needs and stroke prevention. [S]